Abstract
Aromatic amino acid, cysteine sulfinic acid, glutamate and histidine decarboxylases, belonging to group II of pyridoxal 5'-phosphate-dependent enzymes, catalyze the synthesis of dopamine/serotonin, hypotaurine, γ-aminobutyric acid and histamine, respectively. Considering that these reaction products are all essential bioactive molecules, group II decarboxylases have been long studied from an evolutionary, biochemical and pharmacological standpoint. Despite the fact that they all belong to a common fold-type, during evolution each decarboxylase has evolved unique structural elements responsible for its substrate specificity. Combining a literature update with bioinformatic analyses, this review focuses on some structural determinants shared by these enzymes revealing their intrinsic substrate specificity and highlighting the importance of some residues/regions for catalytic competence. In particular, two key structural features emerge: 1) a mobile catalytic loop, and 2) an open-to-close conformation accompanying the apo-holo transition. Drawing attention on these elements is crucial in correlating subtle structural modifications to functional properties for the understanding, at a molecular level of a pathological condition. This is corroborated by the increasingly important role played by these decarboxylases in several different pathological states (autoimmune diseases, type I diabetes, Parkinson's disease, aromatic amino acid decarboxylase deficiency, Tourette's syndrome and cholangiocarcinoma).
Keywords: Pyridoxal 5'-phosphate, aromatic amino acid decarboxylase, cysteine sulfinic acid decarboxylase, glutamate decarboxylase, histidine decarboxylase, Type I diabetes, Stiff-person syndrome, Parkinson's disease, aromatic amino acid decarboxylase deficiency, Tourette's syndrome, cholangiocarcinoma.
Current Medicinal Chemistry
Title:New Insights Emerging from Recent Investigations on Human Group II Pyridoxal 5’-Phosphate Decarboxylases
Volume: 24 Issue: 3
Author(s): Alessandro Paiardini, Giorgio Giardina, Giada Rossignoli, Carla Borri Voltattorni and Mariarita Bertoldi
Affiliation:
Keywords: Pyridoxal 5'-phosphate, aromatic amino acid decarboxylase, cysteine sulfinic acid decarboxylase, glutamate decarboxylase, histidine decarboxylase, Type I diabetes, Stiff-person syndrome, Parkinson's disease, aromatic amino acid decarboxylase deficiency, Tourette's syndrome, cholangiocarcinoma.
Abstract: Aromatic amino acid, cysteine sulfinic acid, glutamate and histidine decarboxylases, belonging to group II of pyridoxal 5'-phosphate-dependent enzymes, catalyze the synthesis of dopamine/serotonin, hypotaurine, γ-aminobutyric acid and histamine, respectively. Considering that these reaction products are all essential bioactive molecules, group II decarboxylases have been long studied from an evolutionary, biochemical and pharmacological standpoint. Despite the fact that they all belong to a common fold-type, during evolution each decarboxylase has evolved unique structural elements responsible for its substrate specificity. Combining a literature update with bioinformatic analyses, this review focuses on some structural determinants shared by these enzymes revealing their intrinsic substrate specificity and highlighting the importance of some residues/regions for catalytic competence. In particular, two key structural features emerge: 1) a mobile catalytic loop, and 2) an open-to-close conformation accompanying the apo-holo transition. Drawing attention on these elements is crucial in correlating subtle structural modifications to functional properties for the understanding, at a molecular level of a pathological condition. This is corroborated by the increasingly important role played by these decarboxylases in several different pathological states (autoimmune diseases, type I diabetes, Parkinson's disease, aromatic amino acid decarboxylase deficiency, Tourette's syndrome and cholangiocarcinoma).
Export Options
About this article
Cite this article as:
Paiardini Alessandro, Giardina Giorgio, Rossignoli Giada, Voltattorni Borri Carla and Bertoldi Mariarita, New Insights Emerging from Recent Investigations on Human Group II Pyridoxal 5’-Phosphate Decarboxylases, Current Medicinal Chemistry 2017; 24 (3) . https://dx.doi.org/10.2174/0929867324666161123093339
DOI https://dx.doi.org/10.2174/0929867324666161123093339 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
GABAA/Bz Receptor Subtypes as Targets for Selective Drugs
Current Medicinal Chemistry Cannabidiol Adverse Effects and Toxicity
Current Neuropharmacology Sodium Channel Blockers as Therapeutic Target for Treating Epilepsy: Recent Updates
Current Topics in Medicinal Chemistry Cyclobutane Biomolecules: Synthetic Approaches to Amino Acids, Peptides and Nucleosides
Current Organic Chemistry Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Meet the Editorial Board
CNS & Neurological Disorders - Drug Targets Glial Cells – The Key Elements of Alzheimer´s Disease
Current Alzheimer Research Novel Insights into V-ATPase Functioning: Distinct Roles for its Accessory Subunits ATP6AP1/Ac45 and ATP6AP2/(pro) Renin Receptor
Current Protein & Peptide Science Dietary Interventions in Children with Autism Spectrum Disorders - An Updated Review of the Research Evidence
Current Clinical Pharmacology Hybrid SPECT/CT Imaging in Neurology
Current Radiopharmaceuticals Neurogenesis and Stroke
CNS & Neurological Disorders - Drug Targets Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine Can Topiramate Induce Pruritus? A Case Report and Review of Literature
CNS & Neurological Disorders - Drug Targets Mitochondrial Encephalomyopathies in Children. Part I: Conventional MR Imaging Findings
Current Medical Imaging Recent Developments in Group I Metabotropic Glutamate Receptor Allosteric Modulators for the Treatment of Psychiatric and Neurological Disorders (2014-May 2015)
Current Topics in Medicinal Chemistry Investigation of the Roles of New Antiepileptic Drugs and Serum BDNF Levels in Efficacy and Safety Monitoring and Quality of Life: A Clinical Research
Current Clinical Pharmacology Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence
Current Drug Abuse Reviews Presynaptic NR2B-Containing NMDA Autoreceptors Mediate Glutamatergic Synaptic Transmission in the Rat Visual Cortex
Current Neurovascular Research Antiepileptic Treatments in Developing Countries
Current Pharmaceutical Design Molecular Imaging at Tohoku University: From Cancer to Neuroreceptors
Current Medical Imaging